June 27, 2017
TapImmune has enrolled 50% (40/80) of the patients in its randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV 200 for treating triple-negative breast cancer (TNBC).
June 22, 2017
TapImmune has entered into definitive subscription agreements to raise aggregate gross proceeds of approximately $6.82 million in a private placement transaction with accredited investors and from the exercise of certain outstanding Series E warrants by certain existing institutional investors.
June 14, 2017
Dr. Glynn Wilson, Chairman and CEO of TapImmune, will present at the 2017 Biotechnology Innovation Organization International Convention held on June 19-22 in San Diego.
June 7, 2017
TapImmune says it is exploring licensing out its nucleic acid-based protein expression technology PolyStart to vaccine developers.
June 6, 2017
Ovarian Cancer News Today has covered TapImmune's cancer vaccine for Ovarian and Breast Cancer, TPIV 200. Take a look.
June 5, 2017
The company is getting closer with several therapies under development, CEO Glynn Wilson said in a quarterly update last week.
June 1, 2017
Here is the complete transcript provided by Seeking Alpha from May 31st conference call and live webcast regarding 2017 first quarter clinical and corporate updates.